NAMS NewAmsterdam Pharma Company NV Forecast, Technical & Fundamental Analysis

NAMS in +3.14% Uptrend, growing for three consecutive days on September 30, 2026

Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where NAMS advanced for three days, in 197 of 244 cases, the price rose further within the following month. The odds of a continued upward trend are 81%.

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where NAMS's RSI Oscillator exited the oversold zone, 19 of 24 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 79%.

The Momentum Indicator moved above the 0 level on September 28, 2026. You may want to consider a long position or call options on NAMS as a result. In 69 of 97 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 71%.

The Moving Average Convergence Divergence (MACD) for NAMS just turned positive on September 22, 2026. Looking at past instances where NAMS's MACD turned positive, the stock continued to rise in 40 of 58 cases over the following month. The odds of a continued upward trend are 69%.

NAMS may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

The Stochastic Oscillator has been in the overbought zone for 2 days. Expect a price pull-back in the near future.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where NAMS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 78%.

The Aroon Indicator for NAMS entered a downward trend on September 25, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 14 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is 57 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock slightly better than average.

The Tickeron Price Growth Rating for this company is 77 (best 1 - 100 worst), indicating slightly worse than average price growth. NAMS’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of 80 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.464) is normal, around the industry mean (26.780). P/E Ratio (29.762) is within average values for comparable stocks, (43.395). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (0.000) among similar stocks. P/S Ratio (357.143) is also within normal values, averaging (438.009).

The Tickeron SMR rating for this company is 97 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.